Aurinia Pharmaceuticals (AUPH) PT Raised to $11 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
March 19, 2019 4:02 PM EDTVICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
2018 and Recent Highlights
Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims which have the potential to cover voclosporins method of use and dosing protocol for lupus nephritis (LN) until December 2037. Phase 2a Dry Eye Study results released in January 2019 demonstrating statistically superior efficacy of... More